15例CD30^+间变性大细胞淋巴瘤临床分析

CD30^+ anaplastic large cell lymphoma:a report of 15 cases

回顾性分析15例CD30+间变性大细胞淋巴瘤(anaplastic large cell lymphoma,ALCL)患者的临床资料。中位年龄36岁,男女比例为1.5∶1。所有病例均经病理证实,均以联合化疗为主,配合局部病灶野放疗3例。化疗方案主要为CHOP、CVAD和BACOP,以CHOP方案为主。有B症状、Ⅲ～Ⅳ期和结外侵犯者分别为60.0%(9/15)、73.3%(11/15)和60.0%(9/15);乳酸脱氢酶升高者为46.7%(7/15);间变性大细胞淋巴瘤激酶阳性9例(60.0%),阴性6例(40.0%)。CR 11例(73.3%),PR 1例(6.7%),SD+PD 3例(20.0%)。

The clinical data of 15 patients with CD30 ＋ anaplastic large cell lymphoma（ ALCL） were retrospectively analyzed. The median age was 36 y and the male to female ratio was 1. 5∶ 1. All cases were confirmed by histopathological examination. Nine cases had B cell symptoms（ 60. 0%）,11 cases were in Ⅲ ～ Ⅳ（ 73. 3%） and 9 cases with invasion outside lymph nodes（ 60. 0%）. Increased lactate dehydrogenase（ LDH）,positive anaplastic large cell lymphoma kinase（ ALK） and negative ALK were detected in 7（ 46.7%）,9（ 60.0%） and 6（ 40.0%） patients,respectively. The patients were treated mainly with chemotherapy regimen CHOP or others（ CVAD and BACOP）,3 patients also received combined radiotherapy. CR was achieved in 11 cases（ 73. 3%）,PR in one case（ 6. 7%） and SD ＋ PD in 3 cases（ 20. 0%）.